HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The muscarinic receptor antagonist propiverine exhibits α(1)-adrenoceptor antagonism in human prostate and porcine trigonum.

AbstractPURPOSE:
Combination therapy of male lower urinary tract symptoms with α(1)-adrenoceptor and muscarinic receptor antagonists attracts increasing interest. Propiverine is a muscarinic receptor antagonist possessing additional properties, i.e., block of L-type Ca(2+) channels. Here, we have investigated whether propiverine and its metabolites can additionally antagonize α(1)-adrenoceptors.
METHODS:
Human prostate and porcine trigone muscle strips were used to explore inhibition of α(1)-adrenoceptor-mediated contractile responses. Chinese hamster ovary (CHO) cells expressing cloned human α(1)-adrenoceptors were used to determine direct interactions with the receptor in radioligand binding and intracellular Ca(2+) elevation assays.
RESULTS:
Propiverine concentration-dependently reversed contraction of human prostate pre-contracted with 10 μM phenylephrine (-log IC(50) [M] 4.43 ± 0.08). Similar inhibition was observed in porcine trigone (-log IC(50) 5.01 ± 0.05), and in additional experiments consisted mainly of reduced maximum phenylephrine responses. At concentrations ≥1 μM, the propiverine metabolite M-14 also relaxed phenylephrine pre-contracted trigone strips, whereas metabolites M-5 and M-6 were ineffective. In radioligand binding experiments, propiverine and M-14 exhibited similar affinity for the three α(1)-adrenoceptor subtypes with -log K (i) [M] values ranging from 4.72 to 4.94, whereas the M-5 and M-6 did not affect [(3)H]-prazosin binding. In CHO cells, propiverine inhibited α(1)-adrenoceptor-mediated Ca(2+) elevations with similar potency as radioligand binding, again mainly by reducing maximum responses.
CONCLUSIONS:
In contrast to other muscarinic receptor antagonists, propiverine exerts additional L-type Ca(2+)-channel blocking and α(1)-adrenoceptor antagonist effects. It remains to be determined clinically, how these additional properties contribute to the clinical effects of propiverine, particularly in male voiding dysfunction.
AuthorsMelinda Wuest, Lambertus P Witte, Martina B Michel-Reher, Stefan Propping, Manfred Braeter, Gerhard J Strugala, Manfred P Wirth, Martin C Michel, Ursula Ravens
JournalWorld journal of urology (World J Urol) Vol. 29 Issue 2 Pg. 149-55 (Apr 2011) ISSN: 1433-8726 [Electronic] Germany
PMID21336600 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Adrenergic alpha-1 Receptor Antagonists
  • Benzilates
  • Calcium Channel Blockers
  • Calcium Channels, L-Type
  • Muscarinic Antagonists
  • Receptors, Adrenergic, alpha-1
  • propiverine
  • Calcium
Topics
  • Adrenergic alpha-1 Receptor Antagonists (pharmacology)
  • Aged
  • Animals
  • Benzilates (pharmacology)
  • Calcium (metabolism)
  • Calcium Channel Blockers (pharmacology)
  • Calcium Channels, L-Type (drug effects)
  • Female
  • Humans
  • Male
  • Middle Aged
  • Models, Animal
  • Muscarinic Antagonists (pharmacology)
  • Muscle Contraction (drug effects)
  • Muscle, Smooth (drug effects, metabolism)
  • Prostate (drug effects, metabolism)
  • Receptors, Adrenergic, alpha-1 (metabolism)
  • Swine
  • Urinary Bladder (drug effects, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: